The glucagon-like peptide-1 (GLP-1) drug class is expected to continue to expand in both the indications the class treats as well as the number of GLP-1 medications brought to market.
Several GLP-1 medications could receive FDA approval to expand the indications they are approved for by the end of 2025, this includes:
💉Ozempic®: Peripheral artery disease with type 2 diabetes
💉Rybelsus®: Major adverse cardiovascular event (MACE) reduction with type 2 diabetes
💉Wegovy®: Heart failure in obesity and for metabolic dysfunction-associated steatohepatitis (MASH)
💉Oral semaglutide currently sold under the trade name Rybelsus® is pending approval for chronic weight management
In 2026, there will likely be an approval for:
✔️High-dose versions of Rybelsus® and Wegovy®
✔️Expanded indication for Mounjaro® for MACE reduction in type 2 diabetes
✔️A new oral GLP-1, Eli Lilly’s orforglipron, approved for both obesity and type 2 diabetes
✔️Semaglutide in the treatment of Alzheimer’s disease
As GLP-1 treatments gain additional indications and new drugs come to market, it's important to have a comprehensive pharmacy benefit management approach in managing utilization. Please contact your ProAct account manager or a member of our dedicated sales team for more information!
https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
